Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

Trial ID or NCT#

NCT01450683

Status

not recruiting iconNOT RECRUITING

Purpose

This study evaluates if itraconazole causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).

Official Title

A Phase 2 Study of Itraconazole in Castrate-resistant Prostate Cancer Post-chemotherapy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: MALE
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Sandy Srinivas
Sandy Srinivas
Medical oncologist, Urologic specialist, Genitourinary specialist
Professor of Medicine (Oncology) and, by courtesy, of Urology

Contact us to find out if this trial is right for you.

Contact

ccto-office@stanford.edu
650-498-7061

View on ClinicalTrials.gov